Skip to content

Repligen RGEN Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

TEC
Bio-TechneTECH
$29.96M+101%
Revvity logo
RevvityRVTY
$5.44M+107%
Agilent Technologies logo
Agilent TechnologiesA
$1M0.0%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$3.4M-20.9%
Charles River Laboratories logo
Charles River LaboratoriesCRL
$1.22M
WAT
Waters CorporationWAT
$3M-62.5%

Other financials

Income statement

See full
Revenue$194.3M+14.8%
Gross profit$108.3M+18.5%
Operating income$15.9M+142%
Net income$8.3M+42.9%
EPS (diluted)$0.15+50.0%

Balance sheet

See full
Cash & equivalents$582.7M-16.4%
Total debt$687.6M+346%
Total equity$2.1B+6.0%
Total assets$2.9B+2.8%

Cash flow

See full
Operating cash flow$28.3M+88.6%
CapEx$4.7M+32.2%
Free cash flow$23.6M+106%

Valuation

See full
Market cap$7.45B-7.1%
Enterprise value$7.55B+2.1%
P/E144.9×
P/S10.1×-0.1×

Profitability

See full
Gross margin49.5%+2.7pp
Operating margin1.5%-14.0pp
Net margin17.1%-3.7pp
FCF margin21.2%+6.1pp

Returns & leverage

See full
Return on equity2.5%+1.9pp
Debt / equity0.3×+0.2×
Current ratio9.2×+2.4×

Where this comes from

Reported directly by Repligen in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Repligen’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Repligen's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Repligen's stock issuance proceeds?
Repligen (RGEN) reported stock issuance proceeds of $0 in Q1 2026.
How has Repligen's stock issuance proceeds changed year-over-year?
Repligen's stock issuance proceeds decreased by 100.0% year-over-year, from $1.46M to $0.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.